Atan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atan

Quick Facts about Trihexyphenidyl

Property Description
Active Ingredient Trihexyphenidyl hydrochloride (INN)
Form Tablet, Oral solution, Elixir
Pharmacological Class Anticholinergic Agent (Antimuscarinic)
General Purpose Symptomatic relief of muscle movement disorders
Origin Synthetic Compound

Defining Atan: Type and Classification

Atan is a trade name for the chemically synthesized, single-ingredient medicine Trihexyphenidyl hydrochloride. It is formally classified as a centrally acting anticholinergic agent, specifically an antimuscarinic drug, belonging to the broader category of antiparkinsonian agents. This classification is clinically recognized for its targeted effect on the central nervous system.

As a synthetic compound, Trihexyphenidyl possesses a defined and consistent chemical structure. It is used as an agent to control extrapyramidal symptoms by inhibiting cholinergic input in the central nervous system. This action distinguishes it as a specific tool for managing movement disorders related to chemical imbalances.


Composition and General Purpose

The active component, Trihexyphenidyl hydrochloride, is the sole ingredient responsible for the drug's therapeutic effects, making it a single-agent product available by prescription only (Rx). It is manufactured for oral administration and is available in multiple dosage forms, including traditional tablets and liquid preparations such as an oral solution or elixir.

The general purpose of this medicine is to provide symptomatic relief for motor control issues. By acting as a muscarinic antagonist, Atan aims to mitigate classic motor symptoms like muscle stiffness and involuntary tremors that impair voluntary movement. The availability of both solid and liquid forms ensures that administration can be adapted to various patient needs, including older adults who may have difficulty swallowing tablets.

Regulatory References

  1. NIH DailyMed: Trihexyphenidyl Hydrochloride Tablet Label

What side effects are possible with Atan?

Possible Side Effects and Safety Information

The safety profile of Trihexyphenidyl (Atan) is primarily defined by its anticholinergic activity, with officially documented adverse reactions classified across several system-organ classes. Many minor effects are reported to be dose-dependent and commonly experienced by 30% to 50% of patients.


Documented Adverse Reaction Scope

Adverse reactions that are common include dry mouth, blurred vision, dizziness, nervousness, and constipation. These typically affect the gastrointestinal, nervous, and ocular systems. The regulatory labeling notes that these effects are often more pronounced at the start of treatment or during dose adjustments, and may subside with continued use.

Serious adverse reactions, though rare, are officially documented and include the risk of acute angle-closure glaucoma, paralytic ileus (severe bowel motility disorder), and severe psychiatric manifestations like hallucinations. Due to its impact on ocular pressure, the medicine is formally contraindicated in patients with narrow-angle glaucoma.


Population and Duration Safety Notes

Regulatory information specifies that older adults frequently exhibit increased sensitivity to the drug, particularly concerning central nervous system side effects such as mental confusion and agitation. Patients with pre-existing conditions, including cardiac, hepatic, or renal disorders, or obstructive diseases of the gastrointestinal or urinary tracts, require specific caution as noted in the product label.

A safety-related constraint involves heat regulation: the drug may impair the body's ability to dissipate heat through perspiration, increasing the risk of hyperthermia. Furthermore, abrupt withdrawal may lead to the exacerbation of symptoms or potentially precipitate a Neuroleptic Malignant Syndrome (NMS)-like reaction.

Overdose and Emergency Response

An overdose of Trihexyphenidyl (Atan) is officially documented as presenting with a central and peripheral anticholinergic syndrome that necessitates immediate action. Seek immediate medical attention if an overdose is suspected, as mandated by regulatory documents.

Documented Manifestations

The clinical presentation involves both severe central nervous system (CNS) and peripheral anticholinergic effects. CNS manifestations documented in regulatory sources include mental confusion, agitation, hallucinations, delirium, and incoordination. Peripheral signs that may manifest are rapid heart rate (tachycardia), severely elevated body temperature (hyperpyrexia), mydriasis (dilated pupils), dry mouth, and urinary retention.

Severe Outcomes and Risks

A severe overdose carries the documented risk of profound CNS depression progressing to coma, circulatory failure, respiratory failure, and potential death if left untreated. Regulatory information specifies that untreated overdose may be fatal, particularly in children. Furthermore, patients with conditions such as arteriosclerosis may exhibit intensified reactions, including severe confusion and disturbed behavior.

Official Management

Treatment is officially defined as symptomatic and supportive care, focusing on maintaining an adequate airway and supporting vital functions. The use of certain pharmacological agents to control excitement or manage central toxicity may be required as part of the established medical treatment protocol.

Therapeutic Uses of Atan

This medication is used across therapeutic domains where additional symptomatic support is needed to address movement disorders. It is primarily applied in managing various forms of Parkinsonism and controlling Extrapyramidal Symptoms (EPS) resulting from certain CNS medications. This supportive relief is relevant in situations involving symptoms of increased neurological or muscular activity.

Atan is used to help with symptom clusters that may become intense or disruptive, including pronounced muscle rigidity, persistent involuntary tremors, and acute dystonic spasms. It is also applied in addressing specific functional symptoms like problematic excessive salivation (sialorrhea). This targeted assistance supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.

“The primary goal is to help maintain a sense of stability when motor symptoms are more noticeable, allowing patients to cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Motor Rigidity and Tremor Atan is typically used to manage symptoms that interfere with daily functioning, supporting mobility and stability in patients with chronic movement disorders.

The medication's role is to provide symptomatic relief across conditions presenting with episodic or fluctuating manifestations, and is used when functional stability becomes affected.

Regulatory References

  1. Official DailyMed Drug Label for Trihexyphenidyl

Eligibility and Restrictions for Use

Trihexyphenidyl (Atan) eligibility is strictly defined by government regulatory agencies, which list both absolute prohibitions and conditional-use populations.

Populations Excluded from Use

The medicine is contraindicated and must not be used by patients with Narrow-Angle Glaucoma or a documented Hypersensitivity to trihexyphenidyl hydrochloride or any of its ingredients.

Age-Related and Condition-Based Restrictions

Population Group Eligibility Status (Regulatory Wording)
Pediatric Patients (Children) Safety and effectiveness have not been established; use is generally not recommended.
Elderly Patients (Geriatric) Exhibit increased sensitivity and require strict dosage regulation and close monitoring.

Eligibility is conditional and requires close observation for patients with underlying medical issues, including Cardiac disorders, Hypertension, Liver (Hepatic) disorders, or Kidney (Renal) disorders. Additionally, caution is advised for patients with Obstructive disease of the Gastrointestinal or Genitourinary tracts and Prostatic Hypertrophy.

Reproductive Status

  • Pregnancy: Use is generally not recommended, but may be permitted if clearly needed.
  • Lactation (Breastfeeding): Should not be used due to potential infant sensitivity and unknown excretion into human milk.

What should I know about interactions with other medicines?

The official regulatory profile for Atan (Trihexyphenidyl) structures its interactions primarily around pharmacodynamic synergy and modified drug exposure.

Interacting Product Classes

Additive Anticholinergic Effects: Co-administration with other Parasympathetic Inhibitors (anticholinergics), Tricyclic Antidepressants, or Monoamine Oxidase Inhibitors (MAOIs) may result in an additive or synergistic increase in antimuscarinic effects, such as dry mouth and urinary retention. The same additive effect is noted with some Phenothiazines, Thioxanthenes, and Butyrophenones. Additionally, caution is advised when co-used with Alcohol or other CNS depressants due to the risk of additive central nervous system depression.

Exposure and Action Modifications

Trihexyphenidyl may antagonize the gastrointestinal action of motility-promoting agents like Metoclopramide and Domperidone. Furthermore, co-administration with Levodopa may reduce Levodopa's absorption, and regulatory documents state that the dose of both drugs may need to be adjusted.

Restrictions and Population Cautions

The medicine is formally contraindicated in patients with Narrow Angle Glaucoma. Official labeling mandates caution in elderly patients, those with CNS disease, or alcoholics, particularly in hot weather or when using other atropine-like drugs, due to a heightened risk of anhidrosis and subsequent hyperthermia. No mandatory timing separation rules are stated in the official documentation.

Mechanism of Action

Atan, or trihexyphenidyl, acts as a non-selective muscarinic acetylcholine receptor antagonist within the central nervous system, particularly in the striatum. The drug crosses the blood-brain barrier to bind to and block all five muscarinic receptor subtypes (M1 to M5), exhibiting higher affinity for the M1 subtype.

This antagonistic interaction decreases the excitatory signaling of the neurotransmitter acetylcholine on postsynaptic neurons. Intracellularly, this blockade prevents the M1-mediated inhibition of adenylyl cyclase, which modulates the signaling cascade involving cyclic AMP. System-level, the central cholinergic inhibition works to re-establish a more homeostatic functional relationship between the cholinergic and dopaminergic pathways in the basal ganglia. The compound also exerts a direct, non-receptor-mediated spasmolytic effect on smooth muscle tissue, in addition to an indirect inhibitory effect on the peripheral parasympathetic nervous system.

Dosage and Administration Information

How to Use Atan (Trihexyphenidyl)

The use of Atan is structured by established clinical protocols, which define the administration route, dosing progression, and precise timing. The medicine is provided for oral administration in the form of tablets (2 mg and 5 mg strengths) or an oral solution (2 mg per 5 mL).


Administration Protocol and Dosing Schedule

Therapy with Trihexyphenidyl must commence with a low initial dose, particularly for idiopathic Parkinsonism, where 1 mg is commonly administered on the first day. The dose is then titrated gradually, typically by increasing the total daily intake by 2 mg every three to five days. This gradual approach continues until the therapeutic maintenance range is achieved, which commonly spans from 6 mg to 10 mg daily, though some patients may require up to 15 mg.

The total daily intake is generally divided into three doses and consumed at mealtimes. For patients on higher total doses, the schedule is modified to four divided doses, with the final dose administered at bedtime.


Contextual and Population-Specific Instructions

The timing relative to food intake is flexible and should be determined by the patient's reaction to the medicine. Administration before meals may be preferred if the medicine tends to cause excessive dry mouth; conversely, taking the medicine after meals is recommended if it causes nausea. When treating older adults (over 60 years of age), it is typically specified that the initial dose must be lower and increased more gradually than for younger adults. It is also a core procedural instruction that treatment must not be stopped abruptly to avoid an acute exacerbation of symptoms.

Recent Clinical Evidence

Research evidence / Overview of Studies for Atan

Evidence for Use in Parkinsonism and Associated Symptoms

Trihexyphenidyl was studied for managing motor symptoms in individuals with Parkinsonism. The research primarily consists of clinical trials and observational settings evaluating daily-life functioning. The studies monitored outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level by measuring changes in symptoms like rigidity and involuntary shaking.

The research highlights changes measured during the study period on standardized clinical scales. Findings describe patterns observed in the studies, particularly in conditions characterized by fluctuating or episodic manifestations. Data show patterns where changes were described for the tremor component compared to other motor issues. Because much of this evidence is older, it contributes to the broader evidence landscape but is not based on the large-scale trials often conducted today.

Long-term effects are not fully established by contemporary research. The evidence for use in the older adult population is constrained by concerns regarding potential central nervous system effects, meaning that certainty remains low around these specific groups.

Evidence for Controlling Drug-Induced Movement Symptoms (EPS)

Research has explored the role of Trihexyphenidyl in individuals who experience movement difficulties, known as Extrapyramidal Symptoms (EPS), caused by certain other medications. This research was evaluated in settings focusing on outcomes describing episodic or acute changes, such as sudden muscle spasms (dystonia) or drug-induced Parkinsonism. The evidence for this use is observed in clinical trials and is supported by widely recognized consensus documents and guidelines.

The studies report how symptoms evolved in the observed populations during periods of heightened symptom activity. The use was observed in studies exploring the acute phase and also in research examining temporary physiological imbalance related to the initiating medication. Comparative evidence is lacking for studies examining a different, long-term movement issue known as tardive dyskinesia.

Research in Dystonia and Symptomatic Excessive Salivation

Trihexyphenidyl was studied for managing dystonia, particularly secondary dystonia in groups like children and adolescents. The research utilized small, dedicated trials, and sample sizes were modest. The findings describe patterns observed in the studies that were often mixed, and evidence quality varies across studies.

Regarding excessive salivation (sialorrhea), research examined this symptom when it occurred in patients with underlying neurological conditions. This evidence largely comes from observational settings and secondary outcomes of trials focused on other issues. This research provides context but not individual predictions, and evidence is limited to short-term symptom monitoring.

What Is Still Uncertain About the Available Research

Evidence highlights what is known — and what is still uncertain. The follow-up durations were limited in many studies, meaning long-term effects are not fully established, and there is a lack of insight into functional outcomes. Data for certain groups remain insufficient, with subgroup findings uncertain. The current research primarily describes group patterns, not personal outcomes.

Key Studies & References

  1. DailyMed Drug Label for Trihexyphenidyl - Definitive Uses and Dosage Forms
  2. WHO ATC/DDD Index: N04AA01 (Trihexyphenidyl)

Frequently Asked Questions (FAQ)

Common questions about Atan (FAQ)


Q: How quickly is Atan expected to start working?

A: According to official pharmacokinetic data, the onset of action for Atan is generally expected to begin within one hour after the medicine is taken orally. This refers to the time it takes for the drug to start affecting the body.


Q: How long does the effect of Atan typically last?

A: The length of time the effects of a single dose last can vary, generally falling between 6 and 12 hours. This duration is one factor in why the total daily amount of the medicine is often divided into multiple doses throughout the day.


Q: Does Atan help with anxiety or is it only for its main purpose?

A: Atan is prescribed for movement disorders and is not indicated for the treatment of anxiety. Official labeling notes that anxiety can sometimes be experienced as an adverse reaction, particularly when the medicine is taken at higher dose levels.


Q: I heard Atan is similar to [other drug]; what is the main difference in how they are described?

A: Official documents note that the medicine's effects are similar to those of atropine, which belongs to the same class of drugs. However, the product labeling suggests that undesirable side effects with Atan are ordinarily less frequent and less severe than with atropine.


Q: Can Atan be taken by people who are sensitive to certain foods?

A: The medicine is formally contraindicated if a person has a known hypersensitivity or allergy to the active ingredient or any of the inactive ingredients, also known as excipients. These inactive ingredients can vary by product form (tablet or liquid). If a person has specific sensitivities, regulatory guidance suggests checking the list of ingredients on the package label.


Q: Are there any widely known non-prescription products that can interact with Atan?

A: Official interaction information indicates that caution is necessary when Atan is used alongside other products, including some available over-the-counter (OTC). Moderate interactions have been reported with common non-prescription medicines such as acetaminophen (a popular pain reliever).


Q: Do you have to take Atan at the exact same time every day?

A: Official instructions advise taking the medicine at around the same time or times every day to maintain consistent levels in the body. Regulatory guidance suggests following the precise directions for timing that are provided on the prescription label.


Q: What happens if a dose of Atan is missed?

A: If a routine dose of Atan is missed, regulatory guidance suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped completely. Official guidance cautions against taking two doses at one time.


Q: Can older adults typically use Atan?

A: Older adults can be prescribed Atan, but official guidance mandates a lower initial starting dose and a slower, more gradual increase. They also require close monitoring due to increased sensitivity, particularly to effects on the central nervous system. Some experts advise avoiding the medicine in the geriatric population due to potential risks.


Q: Is Atan safe to use for a long period of time?

A: The product labeling notes that if the medicine is used for prolonged treatment periods, patients should be closely monitored. This is to check for any unexpected or undesirable reactions that may occur with long-term use.


Q: Is a headache a common side effect when starting Atan?

A: According to official product labeling, headache is listed among the common side effects that have been reported by people using the medicine.


Q: Is it normal to feel a bit tired when you first start taking Atan?

A: Yes, the product labeling notes that effects such as dizziness, weakness, and drowsiness are common side effects that can be experienced with this medicine. These effects are often most noticeable when first starting treatment or when the dose is being adjusted.


Q: Does Atan interact with commonly used over-the-counter pain relievers?

A: Moderate interactions have been reported with commonly used over-the-counter medications such as acetaminophen (a popular pain reliever). Awareness of all products being used is generally recommended, even those purchased without a prescription.


Q: Are there any known issues with taking Atan and caffeine?

A: The official US regulatory labeling does not contain an explicit warning or caution specifically about consuming caffeine. However, caution is advised when using any substance that may affect the central nervous system, including caffeine.


Q: How is Atan classified in terms of controlled substances, if at all?

A: Atan is officially classified as a non-controlled prescription medicine. This means that while it is not subject to the strict scheduling rules of controlled substances, it is still only available when prescribed by a healthcare professional.


Q: Are there any restrictions on diet while using Atan?

A: Official labeling does not list specific food or dietary restrictions to avoid while taking Atan. The only guidance related to food is about the timing of administration relative to meals, which can be adjusted to help manage side effects like dry mouth or nausea.


Q: Is Atan known to cause dependency?

A: The product labeling notes that the medicine has been reported to be abused by some patients. This has sometimes been associated with psychiatric disturbances and is a factor that warrants caution when the medicine is being prescribed.


Q: Where can I find the official Patient Information Leaflet (PIL) for Atan?

A: Detailed consumer information that summarizes the official regulatory labeling is available from government resources. For example, the NIH MedlinePlus website provides drug information to the public based on authoritative sources.


Q: Has Atan been studied in children or adolescents?

A: Official regulatory documents state that the safety and effectiveness of the medicine in the pediatric population (children and adolescents) have not been established. The general regulatory conclusion is that its use is not recommended.


Q: What should I do if I notice a change in how I feel after switching to Atan?

A: Regulatory information states that symptoms such as gastrointestinal problems, fever, or heat intolerance should be promptly reported. This is necessary to allow for appropriate monitoring.


Q: Are there specific symptoms that require immediate medical attention while on Atan?

A: Official warnings describe specific severe symptoms that may necessitate immediate medical evaluation. These include signs of serious adverse reactions like very stiff muscles, a high fever, severe confusion, eye pain, or sudden and severe vision changes.


Q: Does Atan contain any common allergens like gluten or lactose?

A: The official labeling lists all of the inactive ingredients, also known as excipients, in the formulation. However, it does not explicitly name common allergens like gluten or lactose. For specific sensitivities, checking the ingredients list printed on the packaging is recommended.


Q: Is it common for people to switch from another medicine to Atan?

A: Regulatory-based guidance provides procedural instructions for when a patient transitions from another antimuscarinic medicine to Atan. This process involves gradually adjusting the dose of the new medicine upward while simultaneously reducing the dose of the previous medicine.


Q: Why does the packaging for Atan mention [specific inert ingredient]?

A: The packaging is required to list all ingredients. This includes the active ingredient (Trihexyphenidyl) and the inactive ingredients, known as excipients. These excipients are essential for the formation, stability, and delivery of the tablet or liquid form of the medicine.


Q: What is the difference between the brand name and the generic version of Atan?

A: The original brand name for this medicine, Artane, has been discontinued, and it is primarily available today as the generic medicine trihexyphenidyl. Generic products must contain the same active ingredient, strength, and form as the original brand-name product.


Q: Can Atan be taken on an empty stomach?

A: Yes, the medicine can be taken before a meal, which means it may be on a relatively empty stomach. This timing is sometimes preferable if the medicine causes excessive dry mouth. Conversely, if it causes nausea, official instructions advise taking it after a meal.


Q: What is the required monitoring or check-ups mentioned for people on Atan?

A: Regulatory labeling mandates close monitoring of intraocular pressure (eye pressure) at regular intervals due to the risk of angle-closure glaucoma. Close monitoring is also specifically required for patients with pre-existing conditions affecting the heart, liver, or kidneys.


Q: Are there any warnings about driving or operating machinery while taking Atan?

A: Yes, official product labeling contains an explicit warning about this. The medicine may impair the mental and physical abilities needed to perform potentially hazardous tasks, such as driving a motor vehicle or operating heavy machinery.


Q: What is the risk of an allergic reaction to Atan?

A: Having a known hypersensitivity (allergy) to the medicine or any of its ingredients is a formal contraindication. Officially reported allergic reactions may include symptoms such as a skin rash, itching, hives, or swelling of the face, lips, tongue, or throat.


Q: Is it true that Atan has been on the market for a long time?

A: Yes, this medicine has been in use for a long period. It was originally approved by the U.S. Food and Drug Administration (FDA) as a treatment for Parkinson's disease in May 1949.


Q: Does Atan interact with herbal supplements like St. John's wort?

A: The official regulatory labeling does not specifically name St. John's wort or other herbal products in its interaction warnings. However, warnings do exist for drugs with additive effects on the central nervous system (CNS), and some herbal supplements may fall into this category.


Q: Does Atan cause weight gain or loss, according to research?

A: Based on information cited in regulatory documents, weight gain is noted as a potential side effect. This is generally considered a less common adverse reaction.


Q: Are there any known effects of Atan on sleep?

A: Studies have noted that the medicine can affect sleep patterns. Reported adverse effects include poor sleep and alterations to the normal structure of sleep, such as a reduction in REM sleep.


Q: Do official documents mention any possibility of overdose with Atan?

A: Yes, regulatory information provides a description of possible symptoms if an overdose were to occur. These symptoms include severe drowsiness, fever, hallucinations, agitation, and seizures.


Q: Is it possible for Atan to stop working after a while?

A: Regulatory-cited literature mentions that the body may develop a tolerance to the medicine over time. If tolerance develops, it may mean that dose adjustments are required to maintain the observed effect.


Q: What safety measures are described in the clinical trials for Atan?

A: Clinical studies and regulatory guidance emphasize the importance of close monitoring for systemic imbalance and adverse effects during treatment. This vigilance is particularly important for patients with pre-existing conditions, such as those affecting the heart, liver, or kidneys.

How should Atan be stored and disposed of?

How to Store and Dispose of Atan (Trihexyphenidyl)

Atan must be stored and disposed of according to regulatory requirements to ensure its stability and maintain safety.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, between 15 C and 30 C (59 F and 86 F).
Environment Protect from freezing (especially the liquid form), heat, moisture, and direct light.
Container Keep in the original container, tightly closed, and in a light-resistant package.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Official guidance requires that unused or outdated Atan be disposed of promptly. The medicine is not on the list of drugs recommended for flushing; therefore, it must not be poured down a sink or toilet. The safest disposal method is via a formal drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. Empty containers should have all personal information obscured before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atan found in:

A-Z Index: